Prostate Cancer Foundation: Challenge Awards for Metastatic, Lethal Prostate Cancer

The following topic areas are preferred:

• Immunotherapy for the treatment of metastatic, lethal prostate cancer.
• Targeted radionuclide therapy for advanced prostate cancer.
• New systemic precision treatments for metastatic, lethal prostate cancer including those targeting the currently ‘undruggable’.
• First-in-field research on new targets for systemic treatment of metastatic, lethal prostate cancer.
• Mechanisms of resistance to current and investigational drugs targeting the androgen receptor and androgen axis, immune system, chemotherapy, and other targeted agents.
• Correlative research around either clinical trials of novel agents or strategies or standard of care.
• Developing or validating biomarkers that guide therapy in patients or further our understanding of the mechanisms by which therapies work.
• Tumor microenvironment signaling related to cancer progression including the immune component.
• New bioinformatics technologies for analysis of genomic data and big data of clinical outcomes.

Teams of at least 3 investigators from non-profit academic research centers, including one young investigator.

Funding: $1 million per team. (No overhead, Nonprofit).

https://www.pcf.org/wp-content/uploads/2018/01/2018-PCF-Challenge-RFA_FINAL.pdf